Emerging Insights into the Dysregulated Monocyte-Macrophage Axis in Necrotizing Enterocolitis

Authors:

Abstract
Objective: To synthesize correlative human, descriptive transcriptomic, and murine evidence on the role of monocyte-macrophage dysregulation in the pathogenesis of necrotizing enterocolitis (NEC), using a structured evidence-tier framework not previously applied to this literature. Study Design: Narrative synthesis and critical appraisal of the peer-reviewed literature on monocyte and macrophage biology in NEC, organized by evidentiary tier: correlative human biomarker and tissue data, descriptive single-cell transcriptomic profiling, and interventional murine studies (macrophage depletion and ferroptosis inhibition). Results: The preterm intestinal macrophage shows paradoxically elevated TLR4 expression and an immature, fetal-derived phenotype lacking tolerogenic programming. Peripheral monocytopenia, particularly serial percentage decline in absolute monocyte count, correlates with NEC onset and severity across three independent cohorts and offers a zero-cost clinical biomarker. Single-cell transcriptomics identifies four functionally distinct macrophage subpopulations in NEC tissue, dominated by an oxidative-stress-related, injury-amplifying subtype. Murine studies provide supportive evidence for a mechanistic contribution: selective macrophage depletion attenuates transfusion-associated NEC-like injury, and pharmacologic inhibition of macrophage ferroptosis limits epithelial damage. Separately, epithelium-derived HMGB1 activates microglial TLR4, a resident macrophage-lineage population, linking intestinal injury to the neurodevelopmental impairment observed in survivors. Conclusion: Dysregulation of monocyte-macrophage pathways plays a significant role in the pathogenesis of NEC, supported by convergent correlative, descriptive, and interventional evidence. These findings reframe NEC as a disease of myeloid imbalance and identify macrophage-targeted strategies, including TLR4 modulation and ferroptosis-targeted therapy, as rational directions for future prevention and treatment.